Chromosomal segments may explain the antibody response cooperation for canine leishmaniasis pathogenesis
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
BATISTA, Luis F. S.
TORRECILHA, Rafaela B. P.
SILVA, Rafaela B.
UTSUNOMIYA, Yuri T.
PACHECO, Acacio D.
BOSCO, Anelise M.
PAULAN, Silvana C.
ROSSI, Claudio N.
Citação
VETERINARY PARASITOLOGY, v.288, article ID 109276, 12p, 2020
Resumo
Visceral leishmaniasis (VL) is marked by hyperactivation of a humoral response secreting high quantity of immunoglobulins (Igs) that are inaccessible to intracellular parasites. Here we investigated the contributions of the antibody response to the canine leishmaniasis pathogenesis. Using correlation and genome-wide association analysis, we investigated the relationship of anti-Leishmania infantum immunoglobulin classes levels with parasite burden, clinical response, renal/hepatic biochemical, and oxidative stress markers in dogs from endemic areas of VL. Immunoglobulin G (IgG) and IgA were positively correlated with parasite burden on lymph node and blood. Increased IgG, IgA and IgE levels were associated with severe canine leishmaniasis (CanL) whereas IgM was elevated in uninfected exposed dogs. Correlations of IgM, IgG and IgA with creatinine, urea, AST and ALT levels in the serum were suggested an involvement of those Igs with renal and hepatic changes. The correlogram of oxidative radicals and antioxidants revealed a likely relationship of IgM, IgG and IgA with oxidative stress and lipid pemxidation in the blood, suggested as mechanisms mediating tissue damage and CanL worsening. The gene mapping on chromosomal segments associated with the quantitative variation of immunoglobulin classes identified genetic signatures involved with reactive oxygen species generation, phagolysosome maturation and rupture, free iron availability, Thl/Th2 differenciation and, immunoglobulin clearance. The findings demonstrated the roles of the antibody response as resistance or susceptibility markers and mediators of CanL pathogenesis. In addition we pinpointed candidate genes as potential targets for the therapy against the damage caused by exacerbated antibody response and parasitism in VL.
Palavras-chave
GWAS, Canine leishmaniasis, Antiboby response, Oxidative stress, Renal-hepatic changes
Referências
- Almeida BFM, 2013, VET J, V198, P599, DOI 10.1016/j.tvjl.2013.08.024
- Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
- AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858
- Arthur MJP, 1996, J GASTROEN HEPATOL, V11, P1124, DOI 10.1111/j.1440-1746.1996.tb01840.x
- Baig MS, 2015, J EXP MED, V212, P1725, DOI 10.1084/jem.20140654
- Batista LFS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197215
- Batista LFS, 2016, INFECT IMMUN, V84, P3629, DOI 10.1128/IAI.00486-16
- Bellomo F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154805
- Belo VS, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002182
- Brandonisio O, 1996, VET IMMUNOL IMMUNOP, V53, P95, DOI 10.1016/0165-2427(96)05562-6
- Britti D, 2008, VET RES COMMUN, V32, pS251, DOI [10.1007/s11259-008-9121, 10.1007/s11259-008-9121-3]
- Brojatsch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095032
- Cantos-Barreda A, 2018, VET PARASITOL, V260, P63, DOI 10.1016/j.vetpar.2018.08.010
- Cerutti A, 2000, J IMMUNOL, V165, P786, DOI 10.4049/jimmunol.165.2.786
- Ciaramella P, 1997, VET REC, V141, P539, DOI 10.1136/vr.141.21.539
- Courtenay O, 2002, J INFECT DIS, V186, P1314, DOI 10.1086/344312
- De Luna R, 2000, J COMP PATHOL, V122, P213, DOI 10.1053/jcpa.1999.0357
- de Vasconcelos T.C.B., 2017, INFECT GENET EVOL, V47
- DECARVALHO LCP, 1986, CLIN EXP IMMUNOL, V64, P495
- Desjardins M, 1997, J EXP MED, V185, P2061, DOI 10.1084/jem.185.12.2061
- Giunchetti RC, 2019, VET PARASITOL, V271, P87, DOI 10.1016/j.vetpar.2019.05.006
- Han SB, 2005, IMMUNITY, V22, P343, DOI 10.1016/j.immuni.2005.01.017
- HARRIS CH, 1993, VET IMMUNOL IMMUNOP, V36, P1, DOI 10.1016/0165-2427(93)90002-L
- Heidarpour M, 2012, PARASITOL RES, V111, P1491, DOI 10.1007/s00436-012-2985-8
- Hwang IY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072596
- Jacobson LS, 2013, J BIOL CHEM, V288, P7481, DOI 10.1074/jbc.M112.400655
- Janoff EN, 1999, J CLIN INVEST, V104, P1139, DOI 10.1172/JCI6310
- Kanazawa T, 2011, J VET MED SCI, V73, P601, DOI 10.1292/jvms.10-0493
- Kaneko J.J., 1997, CLIN BIOCH DOMESTIC, P932
- Kang HM, 2010, NAT GENET, V42, P348, DOI 10.1038/ng.548
- Kawano M, 2013, ARCH BIOCHEM BIOPHYS, V538, P164, DOI 10.1016/j.abb.2013.08.017
- Kohler AC, 2014, ACTA CRYSTALLOGR D, V70, P384, DOI 10.1107/S1399004713028393
- Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215
- Koutinas AF, 2014, VET PATHOL, V51, P527, DOI 10.1177/0300985814521248
- Krebs LT, 2001, DEV BIOL, V238, P110, DOI 10.1006/dbio.2001.0408
- Lai KN, 2012, NAT REV NEPHROL, V8, P275, DOI 10.1038/nrneph.2012.58
- Lainson R, 2005, MEM I OSWALDO CRUZ, V100, P811, DOI 10.1590/S0074-02762005000800001
- Laurenti MD, 2014, VET PARASITOL, V205, P444, DOI 10.1016/j.vetpar.2014.09.002
- Lofgren R, 1999, BBA-MOL CELL RES, V1452, P46, DOI 10.1016/S0167-4889(99)00112-3
- LUCISANO YM, 1988, IMMUNOLOGY, V65, P171
- Mackay LK, 2015, IMMUNITY, V43, P1101, DOI 10.1016/j.immuni.2015.11.008
- Mencacci A, 1997, J INFECT DIS, V175, P1467, DOI 10.1086/516481
- Moreira VR, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02360-16, 10.1128/aac.02360-16]
- Costa CHN, 2010, REV SOC BRAS MED TRO, V43, P386, DOI 10.1590/S0037-86822010000400010
- NIETO CG, 1992, VET PARASITOL, V45, P33, DOI 10.1016/0304-4017(92)90025-5
- Nisimoto Y, 2014, BIOCHEMISTRY-US, V53, P5111, DOI 10.1021/bi500331y
- Olsson M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133844
- Paltrinieri S, 2010, VET J, V186, P393, DOI 10.1016/j.tvjl.2009.08.019
- Paltrinieri S, 2010, JAVMA-J AM VET MED A, V236, P1184, DOI 10.2460/javma.236.11.1184
- Pinto AJW, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-67
- Plevraki K, 2006, J VET INTERN MED, V20, P228, DOI 10.1892/0891-6640(2006)20[228:EOATOT]2.0.CO;2
- Quinnell RJ, 2003, IMMUNOGENETICS, V55, P23, DOI 10.1007/s00251-003-0545-1
- Reis AB, 2009, VET IMMUNOL IMMUNOP, V128, P87, DOI 10.1016/j.vetimm.2008.10.307
- Robson MG, 2001, J IMMUNOL, V166, P6820, DOI 10.4049/jimmunol.166.11.6820
- Roos A, 2001, J IMMUNOL, V167, P2861, DOI 10.4049/jimmunol.167.5.2861
- Roy N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110843
- Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034
- Seto S, 2011, TRAFFIC, V12, P407, DOI 10.1111/j.1600-0854.2011.01165.x
- Siqueira-Neto JL, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006512
- Solano-Gallego L, 2001, VET PARASITOL, V96, P265, DOI 10.1016/S0304-4017(00)00446-5
- Souza CC, 2014, INT J EXP PATHOL, V95, P260, DOI 10.1111/iep.12080
- Srivastava M., 2017, INFLAMM RES, V66, P323
- STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864
- Taverna M, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-4
- Rodrigues CAT, 2007, VET PARASITOL, V143, P197, DOI 10.1016/j.vetpar.2006.09.003
- Tindemans I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00419
- Todoli F, 2009, VET PARASITOL, V159, P17, DOI 10.1016/j.vetpar.2008.10.010
- Torrecilha RBP, 2016, PREV VET MED, V132, P83, DOI 10.1016/j.prevetmed.2016.08.006
- Utsunomiya YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136749
- WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969
- WILSON ME, 1994, INFECT IMMUN, V62, P3262, DOI 10.1128/IAI.62.8.3262-3269.1994
- Yabuki A, 2016, J VET MED SCI, V78, P513, DOI 10.1292/jvms.15-0161